May 2009
Forbes Asia;5/25/2009, Vol. 5 Issue 9, p6
Correction notice
A correction to the article "Career Comeback," that was published in the May 11, 2009 issue is presented.


Related Articles

  • Calltrion Bringing 50,000 Liters of Cell Culture to South Korea in 2006, Triple by 2010.  // Chemical Market Reporter;3/7/2005, Vol. 267 Issue 10, p7 

    Reports on the production capacity of Celltrion's mammalian cell culture facility in Incheon, South Korea. Market share in biopharmaceutical contract manufacturing; Response to the cost advantage enjoyed by Indian and Chinese fine chemical companies in the small-molecule sector; Partnership with...

  • Hospira Partner Celltrion Halts Trial for Biosimilar Rituxan. Boggs, Jennifer // BioWorld Today;4/19/2013, Vol. 24 Issue 75, p1 

    The article reports on the decision of biopharmaceutical company Celltrion Inc. to stop the late-stage trial on CT-P10, a Rituxan/MabThera (rituximab) biosimilar. The trial compares Celltrion's CT-P10 to MabThera in patients with advanced follicular lymphoma. Celltrion did not disclosed the...

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/11/2008, Vol. 19 Issue 8, p2 

    This section offers world news briefs related to the biotechnology industry. Advanced Cell Technology Inc. in Worcester, Massachusetts, has developed five human embryonic stem cell lines without the destruction of embryos. Celltrion Inc. in Incheon, South Korea, has been hired to supply the...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/29/2007, Vol. 18 Issue 231, p2 

    This section offers news briefs on biotechnology. An exclusive license was granted by Abraxis BioScience Inc. to Green Cross Corp. for the commercialization of Abraxane in Korea. The Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the new drug...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/9/2008, Vol. 19 Issue 69, p6 

    This section offers news briefs related to the biotechnology industries. Full global rights to the I-3D portfolio of orally active, dihydroorotate dehydrogenase inhibiting compounds for the treatment of autoimmune diseases and transplant rejection have been acquired by Chelsea Therapeutics...

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/16/2014, Vol. 25 Issue 11, p2 

    This section offers news briefs on the pharmaceutical industry as of January 2014. Amgen Inc., a biotechnology company, launched a collaboration to discover and validate therapeutic targets and develop therapies for inflammatory bowel disease. Celltrion, Inc. is a company engaged in making...

  • Hospira, Celltrion In Biogeneric Pact.  // Contract Pharma;Nov/Dec2009, Vol. 11 Issue 9, p38 

    The article reports on a business cooperation agreement signed by Hospira Inc. with South Korea-based Celltrion Inc. for the distribution of biogeneric products in the U.S., Europe, Australia, New Zealand and Canada. It notes that Hospira and Celltrion will work together on manufacturing and...

  • BMS Plans to Build $660-Million Bulk Biologics Manufacturing Facility. van Arnum, Patricia // Pharmaceutical Technology;Apr2006, Vol. 30 Issue 4, p22 

    The article reports that Bristol-Myers Squibb Co. (BMS) will build a large-scale multiproduct bulk biologics manufacturing facility in the United States. The project has a capital expenditure of $660 million. The new capacity offered by the biologics facility will be in addition to biologics...

  • Lonza gets hammered by Celltrion activities.  // Chemical Market Reporter;6/27/2005, Vol. 267 Issue 26, p4 

    Reports on the decline in the value of biopharmaceutical company Lonza's stock during the week ending June 26, 2005. Effect of rival contract manufacturer South Korea-based Celltrion's long-term deal with Bristol-Myers Squibb; Company's efforts to bolster its global biopharmaceuticals...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics